You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
3.85億元!中國同輻(01763.HK)附屬中標11台螺旋斷層放射治療系統
格隆匯 11-10 12:21

格隆匯11月10日丨中國同輻(01763.HK)宣佈,近日,公司所屬中核安科鋭(天津)醫療科技有限責任公司(”中核安科鋭“),成功收到國家衞生健康委國際交流與合作中心2022年度螺旋斷層放射治療系統集中採購項目中的11台螺旋斷層放射治療系統中標通知書,中標總金額達人民幣3.85億元,招標編號為0708-2241070LH955。

此次國際公開競爭性招標由中國機械進出口(集團)有限公司受國家衞生健康委國際交流與合作中心委託進行,最終用户為11家已取得甲類大型醫用設備配置證的大型醫院。根據目前大型醫用設備管理目錄,螺旋斷層放射治療系統部份型號和射波刀屬國家衞健委甲類高端放射治療系統,兩個平台在國內的裝機用户總量接近90家,主要集中在省級以上腫瘤醫院、排名靠前的三甲綜合性醫院。

中核安科鋭成立2019年3月26日,是由中國同輻下屬中核高能(天津)準備有限公司出資51%,安科鋭亞洲有限公司出資49%組建而成的中外合資公司。中核安科鋭旗下擁有螺旋斷層放射治療系統(包含Radixact系列,Tomo H系列等機型)和射波刀系統(CyberKnife M6系列)兩款高端放射治療平台,裝備醫院放療科或腫瘤科,主要用於對全身各部位腫瘤和其他病變實施圖像引導下調強放療和立體定向放療。

中核安科鋭已在國內各區域建立完善的銷售、市場和服務團隊,銷售市場團隊擁有豐富的放療行業經驗和專業的放療行業知識。中核安科鋭將秉承”在中國,為中國“的理念,讓更多的中國腫瘤患者能用上好的放療設備,推動高端放療設備國產化、普及化,未來將造福更多腫瘤患者。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account